𝔖 Bobbio Scriptorium
✦   LIBER   ✦

GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action

✍ Scribed by Andrew D. Simmons; Betty Li; Melissa Gonzalez-Edick; Carol Lin; Marina Moskalenko; Thomas Du; Jennifer Creson; Melinda J. VanRoey; Karin Jooss

Book ID
105967236
Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
663 KB
Volume
56
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1/2 dose-escalation study of a GM-
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
✍ Celestia S. Higano; John M. Corman; David C. Smith; Arthur S. Centeno; Christoph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract ## BACKGROUND This open‐label, multicenter, dose‐escalation study evaluated multiple dose levels of immunotherapy in patients with metastatic hormone‐refractory prostate cancer (HRPC). The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate‐carcinoma cell line

Clonal analysis of the action of GM-CSF
Clonal analysis of the action of GM-CSF on the proliferation and differentiation of myelomonocytic leukemic cells
✍ D. Metcalf 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 French ⚖ 734 KB

## Abstract With 214 subclones of the BALB/c myelomonocytic leukemia WEHI‐3B, the granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) in impure or purified form, consistently increased the proportion of colonies exhibiting partial or complete differentiation in agar cultures. GM‐CSF also incr